Everolimus in Anaplastic Thyroid Cancer: A Case Series

被引：23

作者：

Harris, Ethan J. ^{[1
]}

Hanna, Glenn J. ^{[1
]}

Chau, Nicole ^{[1
]}

Rabinowits, Guilherme ^{[2
]}

Haddad, Robert ^{[1
]}

Margalit, Danielle N. ^{[1
]}

Schoenfeld, Jonathan ^{[1
]}

Tishler, Roy B. ^{[1
]}

Barletta, Justine A. ^{[3
]}

Nehs, Matthew ^{[3
]}

Janne, Pasi ^{[1
]}

Huang, Julian ^{[1
,4
]}

Groden, Phillip ^{[5
]}

Kacew, Alec ^{[1
]}

Lorch, Jochen ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Miami Canc Inst, Miami, FL USA

[3] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA

[4] Yale Sch Med, New Haven, CT USA

[5] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

来源：

FRONTIERS IN ONCOLOGY | 2019年 / 9卷

关键词：

anaplastic thyroid cancer (ATC); precision medicine; mTOR inhibition in head and neck cancer; exceptional responder; PI3K mTOR; PHASE-II TRIAL; BRAF; CARCINOMA; SORAFENIB; AXITINIB;

D O I：

10.3389/fonc.2019.00106

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Anaplastic thyroid cancer (ATC) is a very aggressive disease and accounts for over 50% of thyroid-cancer related deaths. mTOR inhibition has shown antitumor activity in ATC. We report our experience treating patients with ATC with everolimus off-protocol. Methods: Patients with con firmed ATC and treated with everolimus at DFCI were identified and reviewed retrospectively. NexGen sequencing was performed, and radiologic responses were correlated with mutational profile. Results: Five patients were treated from 2013 to 2016. Three patients had a response, which included one patient who achieved a partial response for 27.9 months, and two patients who had stable disease for 3.7 and 5.9 months, respectively. Genomic analysis was available in two patients and revealed that the partial responder had mutations involving the PI3K/mTOR pathway. Conclusion: Everolimus has anti-tumor activity in ATC, and responses may correlate with mutations involving the PI3K/mTOR pathway. Further studies are warranted.

引用

页数：6

共 29 条

[1] Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer [J].

Agarwal, Rishi ;

Wang, Jiang ;

Wilson, Keith ;

Barrett, William ;

Morris, John C. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (10) :1203-1207

[2] Integrated Genomic Characterization of Papillary Thyroid Carcinoma [J].

Agrawal, Nishant ;

Akbani, Rehan ;

Aksoy, B. Arman ;

Ally, Adrian ;

Arachchi, Harindra ;

Asa, Sylvia L. ;

Auman, J. Todd ;

Balasundaram, Miruna ;

Balu, Saianand ;

Baylin, Stephen B. ;

Behera, Madhusmita ;

Bernard, Brady ;

Beroukhim, Rameen ;

Bishop, Justin A. ;

Black, Aaron D. ;

Bodenheimer, Tom ;

Boice, Lori ;

Bootwalla, Moiz S. ;

Bowen, Jay ;

Bowlby, Reanne ;

Bristow, Christopher A. ;

Brookens, Robin ;

Brooks, Denise ;

Bryant, Robert ;

Buda, Elizabeth ;

Butterfield, Yaron S. N. ;

Carling, Tobias ;

Carlsen, Rebecca ;

Carter, Scott L. ;

Carty, Sally E. ;

Chan, Timothy A. ;

Chen, Amy Y. ;

Cherniack, Andrew D. ;

Cheung, Dorothy ;

Chin, Lynda ;

Cho, Juok ;

Chu, Andy ;

Chuah, Eric ;

Cibulskis, Kristian ;

Ciriello, Giovanni ;

Clarke, Amanda ;

Clayman, Gary L. ;

Cope, Leslie ;

Copland, John A. ;

Covington, Kyle ;

Danilova, Ludmila ;

Davidsen, Tanja ;

Demchok, John A. ;

DiCara, Daniel ;

Dhalla, Noreen .

CELL, 2014, 159 (03) :676-690

[3] A Multiinstitutional Phase 2 Trial of Pazopanib Monotherapy in Advanced Anaplastic Thyroid Cancer [J].

Bible, Keith C. ;

Suman, Vera J. ;

Menefee, Michael E. ;

Smallridge, Robert C. ;

Molina, Julian R. ;

Maples, William J. ;

Karlin, Nina J. ;

Traynor, Anne M. ;

Kumar, Priya ;

Goh, Boon Cher ;

Lim, Wan-Teck ;

Bossou, Ayoko R. ;

Isham, Crescent R. ;

Webster, Kevin P. ;

Kukla, Andrea K. ;

Bieber, Carolyn ;

Burton, Jill K. ;

Harris, Pamela ;

Erlichman, Charles .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (09) :3179-3184

[4] Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial [J].

Brose, Marcia S. ;

Nutting, Christopher M. ;

Jarzab, Barbara ;

Elisei, Rossella ;

Siena, Salvatore ;

Bastholt, Lars ;

de la Fouchardiere, Christelle ;

Pacini, Furio ;

Paschke, Ralf ;

Shong, Young Kee ;

Sherman, Steven I. ;

Smit, Johannes W. A. ;

Chung, John ;

Kappeler, Christian ;

Pena, Carol ;

Molnar, Istvan ;

Schlumberger, Martin J. .

LANCET, 2014, 384 (9940) :319-328

[5] Treatment with Tyrosine Kinase Inhibitors for Patients with Differentiated Thyroid Cancer: the M. D. Anderson Experience [J].

Cabanillas, Maria E. ;

Waguespack, Steven G. ;

Bronstein, Yulia ;

Williams, Michelle D. ;

Feng, Lei ;

Hernandez, Mike ;

Lopez, Adriana ;

Sherman, Steven I. ;

Busaidy, Naifa L. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (06) :2588-2595

[6] Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC) [J].

Capdevila, Jaume ;

Manuel Trigo, Jose ;

Aller, Javier ;

Luis Manzano, Jose ;

Garcia Adrin, Silvia ;

Zafon Llopis, Carles ;

Reig, Oscar ;

Bohn, Uriel ;

Ramon y Cajal, Teresa ;

Duran-Poveda, Manuel ;

Gonzalez Astorga, Beatriz ;

Lopez-Alfonso, Ana ;

Medina Martinez, Javier ;

Porras, Ignacio ;

Jose Reina, Juan ;

Palacios, Nuria ;

Grande, Enrique ;

Cillan, Elena ;

Matos, Ignacio ;

Jose Grau, Juan .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2017, 177 (04) :309-317

[7] Activating BRAF and PIK3CA Mutations Cooperate to Promote Anaplastic Thyroid Carcinogenesis [J].

Charles, Roch-Philippe ;

Silva, Jillian ;

Iezza, Gioia ;

Phillips, Wayne A. ;

McMahon, Martin .

MOLECULAR CANCER RESEARCH, 2014, 12 (07) :979-986

[8] A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses [J].

Cohen, E. E. W. ;

Tortorici, M. ;

Kim, S. ;

Ingrosso, A. ;

Pithavala, Y. K. ;

Bycott, P. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (06) :1261-1270

[9]

Denaro Nerina, 2013, Onco Targets Ther, V9, P1231, DOI 10.2147/OTT.S46545

[10] Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer [J].

Gibson, William J. ;

Ruan, Daniel T. ;

Paulson, Vera A. ;

Barletta, Justine A. ;

Hanna, Glenn J. ;

Kraft, Stefan ;

Calles, Antonio ;

Nehs, Matthew A. ;

Moore, Francis D., Jr. ;

Taylor-Weiner, Amaro ;

Wala, Jeremiah A. ;

Zack, Travis I. ;

Lee, Thomas C. ;

Fennessy, Fiona M. ;

Alexander, Erik K. ;

Thomas, Tom ;

Janne, Pasi A. ;

Garraway, Levi A. ;

Carter, Scott L. ;

Beroukhim, Rameen ;

Lorch, Jochen H. ;

Van Allen, Eliezer M. .

CLINICAL CANCER RESEARCH, 2017, 23 (09) :2367-2373

← 1 2 3 →